|
業務類別
|
Biotechnology |
|
業務概覽
|
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of chronic disease. The company's oncology asset is TERN-701, a novel, oral allosteric BCR-ABL1 inhibitor for CML currently in Phase 1/2 development. The company's legacy metabolic programs include TERN-501, a clinical-stage thyroid hormone receptor-Beta for MASH and/or obesity, and TERN-801, a glucose-dependent insulinotropic polypeptide receptor antagonist development candidate for obesity. The company is seeking strategic partners to advance the TERN-501 and TERN-801 programs. |
| 公司地址
| 1065 East Hillsdale Boulevard, Suite 100, Foster, CA, USA, 94404 |
| 電話號碼
| +1 650 525-5535 |
| 傳真號碼
| +1 650 275-4254 |
| 公司網頁
| https://www.ternspharma.com |
| 員工數量
| 59 |
| Ms. Melita Sun Jung |
Chief Business Officer |
美元 319.05K |
29/04/2025 |
| Ms. Amy Burroughs, M.B.A. |
Chief Executive Officer and Director |
美元 563.70K |
30/03/2026 |
| Mr. David Eric Strauss |
Corporate Controller and Vice President, Finance |
-- |
24/02/2025 |
| Mr. Andrew Gengos, M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
-- |
30/03/2026 |
| Dr. Emil T. Kuriakose, M.D. |
Chief Medical Officer |
-- |
29/04/2025 |
|
|
| Mr. Robert W. Azelby |
Director |
30/03/2026 |
| Ms. Jill M. Quigley, J.D. |
Independent Director |
30/03/2026 |
| Dr. Hongbo Lu, PhD |
Independent Director |
29/04/2025 |
| Dr. Radhika Tripuraneni, M.D.,M.P.H. |
Independent Director |
30/03/2026 |
| Mr. David Fellows |
Chairman of the Board |
30/03/2026 |
| Ms. Amy Burroughs, M.B.A. |
Chief Executive Officer and Director |
30/03/2026 |
| Ms. Heather D. Turner, J.D. |
Independent Director |
30/03/2026 |
| Mr. Jeffrey B. Kindler, J.D. |
Independent Director |
30/03/2026 |
|
|
|
|
